Martina Reberšek (Author), Nežka Hribernik (Author)

Abstract

Slabost in bruhanje ostajata kljub velikemu napredku najpogostejša neželena učinka sistemskega zdravljenja, ki bistveno zmanjšata bolnikovo kvaliteto življenja in zmanjšata njegovo komplianco za nadaljevanje sistemskega zdravljenja. Priporočila za preprečevanje in zdravljenje slabosti in bruhanja zaradi zdravljenja s citostatiki so bila objavljena leta 2003 v reviji Onkologija. S tem prispevkom dopolnjujemo priporočila za obravnavo slabosti in bruhanja z novostmi, ki so bila objavljena v NCCN smernicah leta 2014 in MASCC in ESMO leta 2010 (1,2).

Keywords

slabost;bruhanje;onkološki bolniki;sistemsko zdravljenje;

Data

Language: Slovenian
Year of publishing:
Typology: 1.04 - Professional Article
Organization: OI - Institute of Oncology
UDC: 616-006
COBISS: 1964155 Link will open in a new window
ISSN: 1408-1741
Parent publication: Onkologija
Views: 2668
Downloads: 586
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: English
Secondary title: Recommendations for prevention and treatment of nausea and vomiting in systemic oncology treatment
Secondary abstract: In spite of great advancement, nausea and vomiting remain the most common undesirable effects of systemic cancer treatment, which substantially lower the patients’ quality of life and reduce their compliance to continue systemic treatment. Recommendations for prevention and treatment of nausea and vomiting resulting from cytostatic treatment were published in 2003 in Oncology magazine. This article complements the recommendations for treatment of nausea and vomiting with new developments, which were published in the NCCN guidelines in 2014 and MASCC and ESMO in 2010 (1, 2). We present our method for treating dysphagia with the help of intraluminal oesophageal stents. In our practice, the intraluminal oesophageal stent has proven to be a very effective and the most patient-friendly method for optimal delivery of nutrients before and during neoadjuvant therapy. There are few complications, and insertions do not have a negative impact on the perioperative outcomes.
URN: URN:NBN:SI
Pages: str. 105-107, 119
Volume: ǂLetn. ǂ18
Issue: ǂšt. ǂ2
Chronology: dec. 2014
ID: 10957701